Akèy › Sarkom tisi mou › Massachusetts › Boston
Etid klinik pou Sarkom tisi mou nan Boston, MA
18 etid pou Sarkom tisi mou ap chèche patisipan nan sit nan ak bò kote Boston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Ap rekriteFaz 1/2
- Dana Farber Cancer Institute., Boston
Anti-GD2 ADC M3554 in Advanced Solid Tumors
Ap rekriteFaz 1
- Dana-Farber Cancer Institute, Boston
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- Dana-Farber Cancer Institute, Boston
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
Ap rekriteFaz 1
- Dana-Farber Cancer Institute, Boston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Ap rekriteFaz 2
- Dana-Farber Cancer Institute - Oncology Department, Boston
Serial MRI Scans During Radiation Therapy
Ap rekrite
- Brigham and Women Hospital, Boston
- Dana Farber Cancer Institute, Boston
Bridging Adolescent and Young Adult Sarcoma Survivors With Personalized Oncology Exercise Service (AYA-ONE): A Pilot Intervention
Ap rekrite
- Boston Children's Hospital, Boston
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
Ap rekriteFaz 1/2
- Dana Farber Cancer Institute, Boston
Distance-Based Exercise to Preserve Function and Prevent Disability
Ap rekrite
- Dana-Farber Cancer Institute, Boston
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
Ap rekriteFaz 1/2
- Dana Farber Cancer Institute, Boston
Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma
Ap rekriteEtid obsèvasyon
- Brigham and Women's Hospital, Boston
Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
Ap rekriteEtid obsèvasyon
- Dana-Farber Cancer Institute, Boston
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Ap rekriteFaz 1/2
- Massachusetts General Hospital,, Boston
Video Education With Result Dependent dIsclosure
Ap rekrite
- Dana Farber Cancer Institute, Boston
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
Ap rekriteFaz 1/2
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
REtroperitoneal SArcoma Registry: an International Prospective Initiative
Ap rekriteEtid obsèvasyon
- Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston
Etid Sarkom tisi mou nan lòt vil
- Houston, TX33 etid
- New York City, NY20 etid
- St. Louis, MO14 etid
- Los Angeles, CA13 etid
- Columbus, OH13 etid
- Washington, DC12 etid
- Memphis, TN11 etid
- Philadelphia, PA10 etid
- Rochester, MN9 etid
- Nashville, TN9 etid
- Queens, NY9 etid
- Aurora, CO9 etid
Lòt etid nan Boston
- Kansè nan tete111 etid
- Kansè Poumon ki pa ti selil89 etid
- Kansè (tout kalite)86 etid
- Kansè kolorektal63 etid
- Kansè Metastatik63 etid
- Kansè poumon62 etid
- Kansè ovè61 etid
- Kansè pwostat60 etid
- Depresyon52 etid
- Kansè Endomèt50 etid
- Leksemi mieloïd egi44 etid
- Kansè pankreyas44 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.